Asset Details
Do you wish to reserve the book?
Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women
Do you wish to request the book?
Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women
2024
Overview
Background
In China, the national cervical cancer screening protocol involves initial testing for high-risk human papillomavirus (hrHPV), followed by cytology for hrHPV-positive cases. This study evaluates the effectiveness of
PAX1
methylation (
PAX1
m
) analysis in identifying precancerous or cancerous lesions in cervical samples from Chinese women positive for non-16/18 hrHPV strains.
Methods
Between February 2022 and March 2023, 281 cervical samples from non-16/18 hrHPV-positive women underwent cytological examination and
PAX1
m
analysis. The study assessed the statistical relationship between
PAX1
m
levels and the presence of cervical lesions, comparing the diagnostic performance of
PAX1
m
to conventional cytology.
Results
A significant association was found between
PAX1
methylation levels and the risk of CIN2 + and CIN3 + lesions, with 47 instances of CIN2 + detected. Odds ratios (ORs) for moderate and high
PAX1
m
levels were 8.86 (95% CI: 2.24–42.17) and 166.32 (95% CI: 47.09-784.97), respectively. The area under the ROC curve for
PAX1
m
in identifying CIN2 + lesions was 0.948 (95% CI: 0.895–0.99).
PAX1
m
demonstrated similar sensitivity and negative predictive value (NPV) to cytology but reduced the colposcopy referral rate from 47.7% with cytology alone to 25.6% with
PAX1
m
, showing superior specificity and positive predictive value across age groups.
Conclusions
PAX1
methylation is a strong indicator of CIN2 + and CIN3 + risk, offering diagnostic performance comparable to cytology with the added benefit of reduced unnecessary colposcopy referrals. These findings support the use of
PAX1
m
analysis as a reliable tool for triaging non-16/18 hrHPV-positive women in outpatient settings.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Analysis
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Biopsy
/ CIN
/ Complications and side effects
/ Cytology
/ Early Detection of Cancer - methods
/ Female
/ Genes
/ Health Promotion and Disease Prevention
/ hrHPV
/ Humans
/ Lesions
/ Oncology
/ Paired Box Transcription Factors - genetics
/ Papillomavirus Infections - complications
/ Papillomavirus Infections - diagnosis
/ Papillomavirus Infections - genetics
/ Papillomavirus Infections - virology
/ Patients
/ Uterine Cervical Dysplasia - diagnosis
/ Uterine Cervical Dysplasia - genetics
/ Uterine Cervical Dysplasia - virology
/ Uterine Cervical Neoplasms - diagnosis
/ Uterine Cervical Neoplasms - genetics
